Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-up

Video

Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.

Fred Saad, MD, FRCS, a professor and chairman of Urology, and director of Genitourinary Oncology at the University of Montreal Hospital Center, spoke with CancerNetwork® during the 2022 European Society for Medical Oncology Congress (ESMO) about updated findings from the phase 3 PROpel trial (NCT03732820), assessing abiraterone (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC).

In patients who received first-line abiraterone and olaparib or abiraterone and placebo, the median overall survival (OS) was not reached, having achieved a maturity of 40.1% (NR; HR, 0.83; 95% CI, 0.66-1.03; P = .11). Moreover, he described the benefit patients with BRCA mutations experienced after receiving the regimen.

Transcript:

What the data we presented here adds to what has already been presented and published is that as the data mature, we're seeing that this trend in overall survival [OS] continues to improve. [It] is very reassuring that we're not seeing a disappearance of that [OS] advantage; it’s actually getting better as the data continues to mature. We’re still only at [approximately] 40% of deaths. The median survival has still not been reached in either arm, which is a good thing for patients, but it tells us that we need to have more time for definite answers regarding [OS].

It also adds to our understanding of the importance of patients with or without mutations, especially BRCA mutations. For [those] who are still wondering about the actual benefit, this answers several questions. Clearly, BRCA-mutated patients are getting tremendous benefit.

Reference

Saad F, Armstrong AJ, Thiery-Vuillemin A, et al. 1357O - Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2022;33(suppl 7):S616-S652. doi:10.1016/annonc/annonc1070

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content